The Manufacturers Life Insurance Company Sells 46,457 Shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO)

The Manufacturers Life Insurance Company trimmed its stake in shares of ALX Oncology Holdings Inc. (NASDAQ:ALXO) by 77.3% during the second quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 13,662 shares of the company’s stock after selling 46,457 shares during the quarter. The Manufacturers Life Insurance Company’s holdings in ALX Oncology were worth $82,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. Swiss National Bank bought a new stake in shares of ALX Oncology during the first quarter valued at about $493,000. Inspire Investing LLC bought a new stake in ALX Oncology during the 1st quarter worth approximately $370,000. Vanguard Group Inc. lifted its stake in ALX Oncology by 4.3% in the 1st quarter. Vanguard Group Inc. now owns 1,566,464 shares of the company’s stock worth $17,466,000 after purchasing an additional 64,055 shares in the last quarter. CANADA LIFE ASSURANCE Co bought a new position in ALX Oncology in the 1st quarter valued at $27,000. Finally, EntryPoint Capital LLC purchased a new position in shares of ALX Oncology during the 1st quarter valued at $32,000. Hedge funds and other institutional investors own 97.97% of the company’s stock.

ALX Oncology Price Performance

Shares of ALX Oncology stock opened at $1.48 on Monday. The business’s 50-day moving average price is $2.06 and its 200-day moving average price is $7.26. The firm has a market capitalization of $77.11 million, a PE ratio of -0.40 and a beta of 1.00. ALX Oncology Holdings Inc. has a 12 month low of $1.42 and a 12 month high of $17.83. The company has a current ratio of 4.39, a quick ratio of 4.39 and a debt-to-equity ratio of 0.06.

ALX Oncology (NASDAQ:ALXO) last posted its quarterly earnings results on Thursday, August 8th. The company reported ($0.76) EPS for the quarter, topping the consensus estimate of ($0.77) by $0.01. Sell-side analysts forecast that ALX Oncology Holdings Inc. will post -3.04 EPS for the current fiscal year.

Analyst Ratings Changes

A number of equities research analysts recently issued reports on the company. HC Wainwright reiterated a “buy” rating and issued a $25.00 price objective on shares of ALX Oncology in a research report on Tuesday, August 13th. Cantor Fitzgerald reaffirmed an “overweight” rating on shares of ALX Oncology in a report on Monday, August 12th. Lifesci Capital lowered ALX Oncology from a “strong-buy” rating to a “hold” rating in a report on Wednesday, July 31st. Stifel Nicolaus reaffirmed a “hold” rating and issued a $3.00 target price (down from $5.00) on shares of ALX Oncology in a research note on Friday, August 9th. Finally, UBS Group cut their price target on shares of ALX Oncology from $25.00 to $4.00 and set a “buy” rating for the company in a research note on Friday, August 16th. Two analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $12.50.

ALX Oncology Profile

ALX Oncology Holdings Inc, a clinical-stage immuno-oncology company, focuses on developing therapies for cancer patients in the United States. The company's lead product candidate is Evorpacept, a CD47 blocking therapeutic biologic in development as a combination therapy with other anti-cancer agents, including ASPEN-06, under Phase 2 clinical study for treating Gastric/GEJ cancer; ASPEN-07, under Phase 1 clinical study for treating urothelial cancer; and ASPEN-03 and ASPEN-04, both under Phase 2 clinical study for treating head and neck squamous cell carcinoma.